The use of isolated domains of type iv collagen to modify cell and tissue interactions
CA 2318432 C · Owner: Sarras, Michael P. Jr. · Inventors: Hudson, Billy G.; Sarras, Michael P. Jr.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The instant invention provides methods and kits for inhibiting angiogenesis tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 .alpha. chain nonomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (.alpha.1), (.alpha.2), (.alpha.3) or (.alpha.6) chain monomer, or , protein constructs having substantially the same structure as the NC1 (.alpha.1), (.alpha.2), (.alpha.3), or (.alpha.6) chain monomer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 26, 1999 and granted January 28, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 26, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 26, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.